Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says

MT Newswires Live10-12 23:07

Gilead Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a physician survey, BofA Securities said in a Monday note.

The investment firm said a Q3 survey of 35 healthcare providers was "supportive of Yeztugo's long-term commercial opportunity."

BofA said continued adoption among new patients, improving access and strong retreatment engagement should support Yeztugo's sustained growth as the product's launch matures. It forecasts Q3 Yeztugo sales of $292 million, above consensus estimates of $290 million.

The firm expects Q3 Biktarvy sales of $3.92 billion, above consensus estimates of $3.91 billion, and Descovy sales of $921 million, above the consensus estimate of $916 million. It forecasts Kite sales of $392 million, slightly above the consensus estimate of $391 million, and Trodelvy sales of $467 million, in line with consensus. Livdelzi sales are forecast at $196 million, below the consensus estimate of $199 million.

BofA remains positive on Gilead's growth prospects, citing its leading HIV franchise and successful product launches as drivers of continued commercial momentum. Beyond HIV treatments, it sees "meaningful upside from the oncology and I&I pipelines as upcoming catalysts advance opportunities for revenue diversification."

BofA reaffirmed its buy rating on Gilead and raised its price target to $168 from $162.

Price: 150.15, Change: -1.02, Percent Change: -0.67

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2674973806?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-12 23:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2674973806","market":"us","top_or_hot":-1,"title":"Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a physician survey, BofA Securities said in a Monday note.</p><p>The investment firm said a Q3 survey of 35 healthcare providers was \"supportive of Yeztugo's long-term commercial opportunity.\"</p><p>BofA said continued adoption among new patients, improving access and strong retreatment engagement should support Yeztugo's sustained growth as the product's launch matures. It forecasts Q3 Yeztugo sales of $292 million, above consensus estimates of $290 million.</p><p>The firm expects Q3 Biktarvy sales of $3.92 billion, above consensus estimates of $3.91 billion, and Descovy sales of $921 million, above the consensus estimate of $916 million. It forecasts Kite sales of $392 million, slightly above the consensus estimate of $391 million, and Trodelvy sales of $467 million, in line with consensus. Livdelzi sales are forecast at $196 million, below the consensus estimate of $199 million.</p><p>BofA remains positive on Gilead's growth prospects, citing its leading HIV franchise and successful product launches as drivers of continued commercial momentum. Beyond HIV treatments, it sees \"meaningful upside from the oncology and I&amp;I pipelines as upcoming catalysts advance opportunities for revenue diversification.\"</p><p>BofA reaffirmed its buy rating on Gilead and raised its price target to $168 from $162.</p><p>Price: 150.15, Change: -1.02, Percent Change: -0.67</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-10-12 23:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GILD\">Gilead</a> Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a physician survey, BofA Securities said in a Monday note.</p><p>The investment firm said a Q3 survey of 35 healthcare providers was \"supportive of Yeztugo's long-term commercial opportunity.\"</p><p>BofA said continued adoption among new patients, improving access and strong retreatment engagement should support Yeztugo's sustained growth as the product's launch matures. It forecasts Q3 Yeztugo sales of $292 million, above consensus estimates of $290 million.</p><p>The firm expects Q3 Biktarvy sales of $3.92 billion, above consensus estimates of $3.91 billion, and Descovy sales of $921 million, above the consensus estimate of $916 million. It forecasts Kite sales of $392 million, slightly above the consensus estimate of $391 million, and Trodelvy sales of $467 million, in line with consensus. Livdelzi sales are forecast at $196 million, below the consensus estimate of $199 million.</p><p>BofA remains positive on Gilead's growth prospects, citing its leading HIV franchise and successful product launches as drivers of continued commercial momentum. Beyond HIV treatments, it sees \"meaningful upside from the oncology and I&amp;I pipelines as upcoming catalysts advance opportunities for revenue diversification.\"</p><p>BofA reaffirmed its buy rating on Gilead and raised its price target to $168 from $162.</p><p>Price: 150.15, Change: -1.02, Percent Change: -0.67</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIB","symbol_name":"Ultra纳斯达克生物科","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2674973806","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2674973806","pubTimestamp":1791817629,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Gilead Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a physician survey, BofA Securities said in a Monday note.The investment firm said a Q3 survey of 35 heal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIB":"Ultra纳斯达克生物科","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0058720904.USD":"联博国际健康护理基金A","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","TMED":"T. Rowe Price Health Care ETF","IBB":"生物科技指数ETF-iShares Nasdaq","BK4583":"猴痘概念","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","GILD":"吉利德科学","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4532":"文艺复兴科技持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","MEDI":"HARBOR HEALTH CARE ETF","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4139":"生物科技","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BBH":"VanEck Biotech ETF","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","BK4578":"CAR-T","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BMED":"iShares Health Innovation Active ETF","SG9999015978.USD":"利安颠覆性创新基金A","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","BK4550":"红杉资本持仓","LU0861579265.USD":"联博低波幅策略股票基金A","BK4588":"碎股","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC"},"translate_title":"美国银行表示，吉利德科学的 Yeztugo 调查支持长期增长前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":0.6,"TBXU":0.6,"TMED":0.6,"BMED":0.6,"IBB":0.6,"BIB":0.6,"MEDI":0.6,"GILD":1.5,"BBH":0.6},"content_text":"Gilead Sciences' (GILD) HIV prevention drug Yeztugo's long-term growth outlook is supported by a physician survey, BofA Securities said in a Monday note.The investment firm said a Q3 survey of 35 healthcare providers was \"supportive of Yeztugo's long-term commercial opportunity.\"BofA said continued adoption among new patients, improving access and strong retreatment engagement should support Yeztugo's sustained growth as the product's launch matures. It forecasts Q3 Yeztugo sales of $292 million, above consensus estimates of $290 million.The firm expects Q3 Biktarvy sales of $3.92 billion, above consensus estimates of $3.91 billion, and Descovy sales of $921 million, above the consensus estimate of $916 million. It forecasts Kite sales of $392 million, slightly above the consensus estimate of $391 million, and Trodelvy sales of $467 million, in line with consensus. Livdelzi sales are forecast at $196 million, below the consensus estimate of $199 million.BofA remains positive on Gilead's growth prospects, citing its leading HIV franchise and successful product launches as drivers of continued commercial momentum. Beyond HIV treatments, it sees \"meaningful upside from the oncology and I&I pipelines as upcoming catalysts advance opportunities for revenue diversification.\"BofA reaffirmed its buy rating on Gilead and raised its price target to $168 from $162.Price: 150.15, Change: -1.02, Percent Change: -0.67","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2674973806","isCrawlerRequest":true}